Zobrazeno 1 - 10 of 12 pro vyhledávání: '"Melanie Hemmrich"'
1
Dissociation between the pharmacokinetics and pharmacodynamics of once‐daily rivaroxaban and twice‐daily apixaban: a randomized crossover study
Autor: Dagmar Kubitza, Pontus B. Persson, Kirstin Thelen, Stefan Heitmeier, Melanie Hemmrich, Reinhold Kreutz, Michael Becka, Stephan Schwers
Publikováno v: Journal of Thrombosis and Haemostasis. 15:2017-2028
Essentials In this crossover study the anticoagulant effects of rivaroxaban and apixaban were compared. Healthy volunteers received rivaroxaban 20 mg once daily or apixaban 5 mg twice daily. Rivaroxaban was associated with more prolonged inhibition o
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e7d082f000a4cbf58f1e2377bd2dc7d
https://doi.org/10.1111/jth.13801
Zobrazit plný text záznamu
2
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study
Autor: Melanie Hemmrich, Stephan Windecker, Ana Denise Zazula, George Dangas, Jan Tijssen, Usman Baber, Pascal Vranckx, Ana H.C. Guimarães, Marco Valgimigli, Roxana Mehran, Albert A. Volkl, Robert C. Welsh, Gerrit-Anne van Es, Karen Thomitzek, Gennaro Giustino, Peter Wildgoose
Publikováno v: Windecker, Stephan; Tijssen, Jan; Giustino, Gennaro; Guimarães, Ana H C; Mehran, Roxana; Valgimigli, Marco; Vranckx, Pascal; Welsh, Robert C.; Baber, Usman; van Es, Gerrit-Anne; Wildgoose, Peter; Volkl, Albert A.; Zazula, Ana; Thomitzek, Karen; Hemmrich, Melanie; Dangas, George D. (2016). Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study. American Heart Journal, 184, pp. 81-87. Elsevier 10.1016/j.ahj.2016.10.017
American heart journal, 184, 81-87. Mosby Inc.
Background Optimal antithrombotic treatment after transcatheter aortic valve replacement (TAVR) is unknown and determined empirically. The direct factor Xa inhibitor rivaroxaban may potentially reduce TAVR-related thrombotic complications and prematu
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77c3fcc93d5afc5f4da006d86ac9439c
https://doi.org/10.1016/j.ahj.2016.10.017
Zobrazit plný text záznamu
4
FRI0303 THE EFFECTS OF RIOCIGUAT ON RAYNAUD’S PHENOMENON AND DIGITAL ULCERS IN PATIENTS WITH DIFFUSE SYSTEMIC SCLEROSIS: RESULTS FROM THE PHASE IIB RISE-SSC STUDY
Autor: Oliver Distler, Janet E. Pope, J. Pena, Zhen Yao, Masataka Kuwana, Melanie Hemmrich, Kaisa Laapas, Christopher P. Denton, Marco Matucci-Cerinic, Dinesh Khanna, Yannick Allanore
Publikováno v: Scleroderma, myositis and related syndromes.
Background Riociguat is a soluble guanylate cyclase stimulator approved for treatment of pulmonary arterial hypertension associated with connective tissue disease. Through its vasodilatory and anti-remodeling properties, it was predicted that riocigu
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::feaec4f4a28634622235e0314bd7f35e
https://doi.org/10.1136/annrheumdis-2019-eular.5755
Zobrazit plný text záznamu
7
Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation
Autor: Riccardo Cappato, Michael D. Ezekowitz, Allan L. Klein, A. John Camm, Chang-Sheng Ma, Jean-Yves Le Heuzey, Mario Talajic, Maurício Scanavacca, Panos E. Vardas, Paulus Kirchhof, Melanie Hemmrich, Vivian Lanius, Isabelle Ling Meng, Peter Wildgoose, Martin van Eickels, Stefan H. Hohnloser
Publikováno v: European Heart Journal. 35:3346-3355
Aims X-VeRT is the first prospective randomized trial of a novel oral anticoagulant in patients with atrial fibrillation undergoing elective cardioversion. Methods and results We assigned 1504 patients to rivaroxaban (20 mg once daily, 15 mg if creat
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0feac00a13b931be61e514facd97b077
https://doi.org/10.1093/eurheartj/ehu367
Zobrazit plný text záznamu
8
Spotlight on unmet needs in stroke prevention: The PIONEER AF-PCI, NAVIGATE ESUS and GALILEO trials
Autor: Karen Thomitzek, Melanie Hemmrich, Jeffrey I. Weitz, Eric D. Peterson
Publikováno v: Thrombosis and haemostasis. 116(Suppl. 2)
SummaryAtrial fibrillation (AF) is a major healthcare concern, being associated with an estimated five-fold risk of ischaemic stroke. In patients with AF, anticoagulants reduce stroke risk to a greater extent than acetylsalicylic acid (ASA) or dual a
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0eddc9b8bc8cbaf7b3b1d0abc1349f91
https://pubmed.ncbi.nlm.nih.gov/27623683
Zobrazit plný text záznamu
9
Levels of macrophage migration inhibitory factor and glucocorticoids in chronic wound patients and their potential interactions with impaired wound endothelial progenitor cell migration
Autor: Melanie Hemmrich, Lena Katharina Eckert, Guy C. M. Steffens, Norbert Pallua, Gerrit Grieb, David Simons, Jürgen Bernhagen
Publikováno v: Wound Repair and Regeneration. 20:707-714
Macrophage migration inhibitory factor (MIF), a structurally and functionally unique pleiotropic mediator in inflammation and immune processes, was identified decades ago. There is now strong evidence that MIF promotes revascularization and is involv
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6b7fa127a2bee5abb84f3f1bf1567abb
https://doi.org/10.1111/j.1524-475x.2012.00817.x
Zobrazit plný text záznamu
10
Abstract 19504: Factors Predicting Sinus Rhythm in Patients Cardioverted in the X-VERT Study
Autor: Michael D Ezekowitz, Riccardo Cappato, Allan Klein, Isabelle L Ming, Melanie Hemmrich, Martin van Eickels, Stefan H Hohnloser
Publikováno v: Circulation. 130
Introduction: The X-VERT trial is the first large, prospective study of a novel oral anticoagulant in patients undergoing elective cardioversion. Patients were randomized to rivaroxaban (20mg or 15mg once daily if the CrCl was between 30 and 49 ml/mi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5ed740bc810cb5c5b82d6265610d3789
https://doi.org/10.1161/circ.130.suppl_2.19504
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje